VIOLA ZILBER: Open Payments
NPI 1881826162 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$710 in 31 payments from 11 companies in 2025. Trend: 2023 $403 · 2024 $926 · 2025 $710
Food & beverage: $710
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $158 |
| AstraZeneca Pharmaceuticals LP | 5 | $115 |
| Regeneron Healthcare Solutions, Inc. | 4 | $90 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $88 |
| GENZYME CORPORATION | 2 | $58 |
| Amgen Inc. | 2 | $51 |
| Incyte Corporation | 2 | $41 |
| LEO Pharma Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| ALK-Abello, Inc | 1 | $23 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NEFFY, BREZTRI, TEZSPIRE, OPZELURA, NUCALA, AIRSUPRA.
Industry payments across NY — which companies pay providers there.
